DDInter640 DDInter782
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unre
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Encorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifaximin
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Grepafloxacin
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Encorafenib may lead to a major life threatening interaction when taken with Grepafloxacin
Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib